===============================================================================
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
Current Report Pursuant to Section 13 or 15(d) of
the Securities Exchange Act of 1934
Date of Report: June 23, 1998 - Commission File No. 0-17746
------------- -------
SAFE TECHNOLOGIES INTERNATIONAL INCORPORATED
(Formerly Safe Aid Products Incorporated)
----------------------------------------------------
(Exact name of Registrant as specified in its Charter)
Delaware 22-2824492
------------------------------- ---------------------
(State or other jurisdiction of (IRS Employer ID No.)
incorporation or organization)
249 Peruvian Avenue
Suite F2
Palm Beach, Florida 33480
------------------------------- ----------
(Address of principal executive (Zip Code)
offices)
Registrant's telephone number,
including area code: (561) 832-2700
--------------
* On February 9, 1998, Safe Aid Products Incorporated merged with and into
Intelligence Network International and was renamed Safe Technologies
International Incorporated.
=============================================================================
<PAGE>
Item 5. Other Events
The Company issued a press release today announcing that one of
its whole owned subsidiaries had entered into a contract with AT&T. The
information contained in the press release, a copy of which is attached
hereto as Exhibit 99.1 is incorporated herein by reference.
<PAGE>
Signatures
----------
Pursuant to the requirements of the Securities Exchange Act of 1934, the
Registrant has duly caused this report to be signed on its behalf by the
undersigned hereunto duly authorized.
SAFE AID PRODUCTS INCORPORATED
By: /s/ Barbara Tolley
--------------------------
Barbara Tolley, President
Dated: June 23, 1998
[logo]
EXHIBIT 99.1
FOR IMMEDIATE RELEASE
SFAD's NEW MANAGEMENT PLANS TO ELIMINATE HEADACHES
Palm Beach, FL. June 22, 1998/PR Newswire/ Safe Technologies
International, Inc., (OTC: SFAD) announced today that
pursuant to SFAD New Management's commitment to Stockholders
at a Special Meeting in Long Island, New York, on January
30th, 1998, to concentrate on evaluating, contacting and
securing potential joint ventures and/or licensees in order
to bring the company's nasal aspirin patent forward,
Management is making 'progress' toward that end.
SFAD first came into prominence with the development of a
Nasal Patent in 1988. Many, loyal SFAD Stockholders have
held their SFAD stock for 8-10 years in hopes that the
Patent would launch. Stockholders expressed their opinions
at the Stockholders Meeting and requested that New
Management put time and effort on developing the Patent.
Initial market evaluations today indicate the marketplace
to be very receptive to new drug technologies.
The invention relates to a novel method of administering
aspirin to achieve improved delivery thereof. The invention
further relates to novel dosage forms of neutralized aspirin
adapted for nasal administration, such as solutions,
suspensions, gels, and ointments. These dosage forms find
utility in the treatment of conditions known to respond to
the administration of aspirin, particularly in the treatment
of migraine, in the mitigation of cardiovascular damage
resulting from heart attack, and in the treatment of acute
pain, such as post operative pain.
"Research in the field of nasal delivery has shown us that
lower dosages of aspirin are required when administered,
faster pain relief due to entering the blood stream more
rapidly, and longer periods of effectiveness with a lack of
any irritation. The aspirin product can be administered
easily by a user through a spray dispenser with controlled
dosage, according to Barbara Tolley, CEO of SFAD."
The company believes the product will be especially
important for those who cannot tolerate aspirin when taken
orally, and for at risk people suffering heart attacks prior
to the arrival of the Emergency Unit, who could administer,
for themselves, a safe immediate aspirin dosage.
According to Ms.Tolley, "One of the first things which we
have done to further develop the Patent is to name the
product. During the last 10 years, the product had no name;
everyone referred to a nameless commodity. For me, coming
from an advertising background, 'branding of a product is
very important.' I believe that we have come up with an
extremely appropriate name for the Nasal Aspirin Patent:
CYRANOL, and are currently preparing to file for trademark
status.
While we are presently talking with two U.S. based
laboratories which have expressed interest in the Patent, we
will be communicating with additional prospective companies,
in the U.S. and abroad, to fully evaluate the best option
for SFAD to pursue."
<PAGE>
Safe Technologies International, based in Palm Beach,
Florida, is a multi-faceted company with multiple areas of
concentration: Internet products, services, and Internet
Directories; Marketing, Advertising, and Digital Pre Press
Graphics and Printing; customized Personal Computer systems
and networks; Heath Care/Wellness related products and
services, such as, i.e.. SFAD's Nasal Aspirin Patent; and
Real Estate products, services, and software.
Forward-Looking Statements: Except for the historical
information contained herein, this news release may contain
forward looking statements within the meaning of Section 27A
of the Securities Act of l934, as amended, that may involve
risks and uncertainties, including those relating to the
availability of suitable financial resources, the
availability of management, as well as other risks detailed
from time to time in the Company's SEC reports, including
reports on Form 10KSB for the year ended November, 1997 and
Form 10-QSB for the quarter ended March 31, 1998.
SOURCE: Safe Technologies International, Inc., (SFAD)
CONTACT: Safe Technologies International, Inc., (SFAD)
TEL: 561-832-2700
EMAIL: [email protected]
HTTP:// www.safetechnologies.com
